TABLE 1.
Study | Method | Internal standard | Blood volume (μl) | Sample preparation | Elution | Column | Mobile phase | Linearity range (ng/ml) | Analytical time (min) | Accuracy (%) |
---|---|---|---|---|---|---|---|---|---|---|
Salm, Taylor et al. (2000) | HPLC-MS | 32-O-desmethoxysirolimus | 500 | PPT by ACN and ZnSO4, followed by SPE | Isocratic | Novapak C18 column (150 mm × 2.1 mm, 4 μm) | 80% MeOH, 20% 50 mM NH4AC, pH 5.1 | 0.2–100 | 10 | 94.4–104.4 |
Zochowska, Bartlomiejczyk et al. (2006) | HPLC-UV | Desmethoxyrapamycin | 1500 | PPT and extracted with 1-chlorobutan | Isocratic | Supelco RP C16-Amide column (150 mm × 4.6 mm, 5 μm) | 60% ACN in water | 3–50 | 15 | NR |
O'Halloran and Ilett (2008) | LC-MS/MS | Desmethoxyrapamycin Sirolimus-d3 | 15 | PPT by ACN and ZnSO4 | Gradient | Supelco C18 column (250 mm × 4.6 mm; 5 µm) | 1 ml/L FA and 2 mM NH4AC in MeOH and water | 1–50 | 2.5 | NR |
Morgan, Brown et al. (2014) | LC-MS/MS | 13C2D4-everolimus | 20 | PPT by ACN and NH4HCO3 and ZnSO4 | Gradient | Waters Symmetry C18 column (50 mm × 2.1 mm, 3.5 μm) | 2 mM NH4AC and 0.1% FA in MeOH and water | 1–49 | 6 | 90.7–113.16 |
Shi et al. (2016) | PS-MS/MS | Sirolimus-d3 | 200 | PPT by MeOH and dried | NR | NR | NR | LLOQ: 2 | NR | NR |
This study | LC-MS/MS | Sirolimus-d3 | 100 | PPT by MeOH | Gradient | Kinetex C18 column (50 mm × 2.1 mm, 1.7 μm) | 0.1 mM FA and 0.05 mM NH4AC in MeOH and water | 0.5–50 | 3 | 88.7–111.8 |
Abbreviations: HPLC-MS, high-performance liquid chromatography–mass spectrometry; HPLC-UV, high-performance liquid chromatography–ultraviolet; LC-MS/MS, high-performance liquid chromatography–tandem mass spectrometry; PS-MS/MS, paper spray–tandem mass spectrometry; PPT, protein precipitation; ACN, acetonitrile; ZnSO4, zinc sulfate; NH4HCO3, ammonium bicarbonate; MeOH: methanol; SPE, solid-phase extraction; NR, not reported; C18, octadecyl carbon chain; NH4AC, ammonium acetate; FA, formic acid; LLOQ, lower limit of quantitation.